Blood Res.  2020 Dec;55(4):200-205. 10.5045/br.2020.2020174.

Radiotherapy for non-gastric intestinal versus gastric MALT lymphoma: a comparison of treatment outcomes

• Watanabe S
• Ogino I
• Hata M

• KMID: 2509958
• DOI: http://doi.org/10.5045/br.2020.2020174

Abstract

Background
Radiotherapy is often used for treating patients with gastric mucosa-associated lymphoid tissue (MALT) lymphomas who fail to respond to Helicobacter pylori eradication. However, non-gastric intestinal MALT lymphoma is rare, and no standard therapeutic strategies have been established. This study was designed to assess the long-term prognosis of non-gastric intestinal MALT lymphoma treated with radiotherapy and to compare the outcomes with that of post-radiotherapy gastric MALT lymphoma.
Methods
The study included 34 patients with stage I EA gastrointestinal MALT lymphoma according to the Ann Arbor classification who underwent definitive radiotherapy. The primary site was the rectum in 3, the duodenum in 1, and the stomach in 30 patients. The radiotherapy dose was 1.5‒2.0 Gy (median, 1.5 Gy) and the total dose was 30‒40 Gy (median, 30 Gy). The clinical target volume (CTV) was defined as the volume of the entire organ with the lymphoma. Adjacent lymph node areas were not routinely included in the CTV.
Results
Complete response (CR) was achieved in all patients. There were no local recurrences, and two cases of recurrence were observed at other sites. The 5-year overall survival rates for non-gastric and gastric MALT lymphomas were 100% and 94.7%, respectively, and the 5-year disease-free survival rates were 100% and 95.7%, respectively. None of the patients died of the current illness.
Conclusion
Radiotherapy for non-gastric intestinal MALT lymphoma is expected to result in good local control and long-term survival, similar to that for gastric MALT lymphoma.

Keyword

Non-gastric intestinal MALT lymphoma; Gastric MALT lymphoma; Radiotherapy; Survival; Local control

Figure

• 

  Fig. 1 The Kaplan–Meier curves for disease-free survival of the 4 non-gastric intestinal and 30 gastric MALT lymphoma patients.

• 

  Fig. 2 The Kaplan–Meier curves for overall survival of the 4 non-gastric intestinal and 30 gastric MALT lymphoma patients.

Reference

1. Olszewska-Szopa M, Wróbel T. 2019; Gastrointestinal non-Hodgkin lymphomas. Adv Clin Exp Med. 28:1119–24. DOI: 10.17219/acem/94068. PMID: 31414733.

2. Weindorf SC, Smith LB, Owens SR. 2018; Update on gastrointestinal lymphomas. Arch Pathol Lab Med. 142:1347–51. DOI: 10.5858/arpa.2018-0275-RA. PMID: 30407861.

3. Swerdlow SH, Campo E, Pileri SA, et al. 2016; The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 127:2375–90. DOI: 10.1182/blood-2016-01-643569. PMID: 26980727. PMCID: PMC4874220.

4. Thieblemont C, Bertoni F, Copie-Bergman C, Ferreri AJ, Ponzoni M. 2014; Chronic inflammation and extra-nodal marginal-zone lymphomas of MALT-type. Semin Cancer Biol. 24:33–42. DOI: 10.1016/j.semcancer.2013.11.005. PMID: 24333758.

5. Wöhrer S, Kiesewetter B, Fischbach J, et al. 2014; Retrospective comparison of the effectiveness of various treatment modalities of extragastric MALT lymphoma: a single-center analysis. Ann Hematol. 93:1287–95. DOI: 10.1007/s00277-014-2042-z. PMID: 24633660.

6. Zullo A, Hassan C, Cristofari F, et al. 2010; Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol. 8:105–10. DOI: 10.1016/j.cgh.2009.07.017. PMID: 19631287.

7. Thieblemont C, Dumontet C, Bouafia F, et al. 2003; Outcome in relation to treatment modalities in 48 patients with localized gastric MALT lymphoma: a retrospective study of patients treated during 1976-2001. Leuk Lymphoma. 44:257–62. DOI: 10.1080/1042819021000035680. PMID: 12688342.

8. Goda JS, Gospodarowicz M, Pintilie M, et al. 2010; Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy. Cancer. 116:3815–24. DOI: 10.1002/cncr.25226. PMID: 20564130.

9. Aleman BM, Haas RL, van der Maazen RW. 2010; Role of radiotherapy in the treatment of lymphomas of the gastrointestinal tract. Best Pract Res Clin Gastroenterol. 24:27–34. DOI: 10.1016/j.bpg.2009.12.002. PMID: 20206106.

10. Amouri A, Chtourou L, Mnif L, et al. 2009; MALT lymphoma of the rectum: a case report treated by radiotherapy. Cancer Radiother. 13:61–4. DOI: 10.1016/j.canrad.2008.11.001. PMID: 19101191.

11. Isomoto H, Kamihira S, Matsuo E, et al. 2003; A case of mucosa- associated lymphoid tissue lymphoma of the ampulla of Vater: successful treatment with radiation therapy. Eur J Gastroenterol Hepatol. 15:1037–41. DOI: 10.1097/00042737-200309000-00016. PMID: 12923379.

12. Rosenberg SA, Boiron M, DeVita VT Jr, et al. 1971; Report of the Committee on Hodgkin's Disease Staging Procedures. Cancer Res. 31:1862–3.

13. Rohatiner A, d'Amore F, Coiffier B, et al. 1994; Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol. 5:397–400. DOI: 10.1093/oxfordjournals.annonc.a058869. PMID: 8075046.

14. Zucca E, Copie-Bergman C, Ricardi U, et al. 2013; Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 24(Suppl 6):vi144–8. DOI: 10.1093/annonc/mdt343. PMID: 24078657.

15. Dreyling M, Thieblemont C, Gallamini A, et al. 2013; ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol. 24:857–77. DOI: 10.1093/annonc/mds643. PMID: 23425945.

16. Nakamura S, Sugiyama T, Matsumoto T, et al. 2012; Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut. 61:507–13. DOI: 10.1136/gutjnl-2011-300495. PMID: 21890816.

17. Nosaka K, Shono T, Yonemura Y, et al. 2014; Regression of primary rectal MALT lymphoma after Helicobacter pylori eradication. Rinsho Ketsueki. 55:948–52. PMID: 25186484.

18. De Sanctis V, Marignani M, Angeletti S, et al. 2012; Anti-Helicobacter pylori therapy in primary MALT lymphoma of rectum. Tumori. 98:e105–10. DOI: 10.1177/030089161209800423. PMID: 23052174.

19. Salar A. 2019; Gastric MALT lymphoma and Helicobacter pylori. Med Clin (Barc). 152:65–71. DOI: 10.1016/j.medcli.2018.09.006. PMID: 30424932.

20. Kajihara Y. 2018; Mucosa-associated lymphoid-tissue (MALT) lymphoma of the rectum. QJM. 111:573. DOI: 10.1093/qjmed/hcy036. PMID: 29474645.

21. Tokura T, Nishikawa S, Umehara M, et al. 2015; A case of MALT lymphoma of the rectum treated with intersphincteric resection (ISR). Gan To Kagaku Ryoho. 42:2265–7. PMID: 26805332.

22. Hayakawa T, Nonaka T, Mizoguchi N, et al. 2017; Radiotherapy for mucosa-associated lymphoid tissue (MALT) lymphoma of the rectum: a case report. Clin J Gastroenterol. 10:431–6. DOI: 10.1007/s12328-017-0769-5. PMID: 28815477.

23. Schmelz R, Miehlke S, Thiede C, et al. 2019; Sequential H. pylori eradication and radiation therapy with reduced dose compared to standard dose for gastric MALT lymphoma stages IE & II1E: a prospective randomized trial. J Gastroenterol. 54:388–95. DOI: 10.1007/s00535-018-1517-4. PMID: 30327875.

24. Teckie S, Qi S, Lovie S, et al. 2015; Long-term outcomes and patterns of relapse of early-stage extranodal marginal zone lymphoma treated with radiation therapy with curative intent. Int J Radiat Oncol Biol Phys. 92:130–7. DOI: 10.1016/j.ijrobp.2015.01.040. PMID: 25863760.

25. Pinnix CC, Gunther JR, Milgrom SA, et al. 2019; Outcomes after reduced-dose intensity modulated radiation therapy for gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Int J Radiat Oncol Biol Phys. 104:447–55. DOI: 10.1016/j.ijrobp.2019.02.002. PMID: 30769175. PMCID: PMC6839887.

26. Hatayama Y, Aoki M, Kawaguchi H, et al. 2017; Safe and successful birth following pelvic radiotherapy for rectal mucosa-associated lymphoid tissue lymphoma: a case report. J Med Case Rep. 11:26. DOI: 10.1186/s13256-016-1193-z. PMID: 28143501. PMCID: PMC5286565.